Advertisement

Role of fibrates in the management of hypertriglyceridemia

  • Daniel J Rader
    Correspondence
    Address for reprints: Daniel J. Rader, MD, University of Pennsylvania Health System PMC Campus, 432 Philadelphia Heart Institute, 51 North 39th Street, Philadelphia, Pennsylvania 19104-2699
    Affiliations
    Department of Medicine, University of Pennsylvania Health System, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Search for articles by this author
  • Steven M Haffner
    Affiliations
    Division of Clinical Epidemiology, University of Texas Health Science Center, San Antonio, Texas, USA
    Search for articles by this author

      Abstract

      Elevated plasma triglyceride levels are increasingly recognized as a risk factor for cardiovascular disease. Fibric acid derivatives (fibrates) substantially decrease triglyceride levels and have been demonstrated to decrease clinical cardiovascular events in some trials. Ongoing research will elucidate the molecular mechanisms by which fibrates modify lipoprotein metabolism, clarify their use in combination with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), and determine their role in the prevention of cardiovascular events.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hokanson J.E
        • Austin M.A
        Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol.
        J Cardio Risk. 1996; 3: 213-219
        • Santamarina-Fojo S
        • Brewer Jr, H.B
        The familial hyperchylomicronemia syndrome. New insights into underlying genetic defects.
        JAMA. 1991; 265: 904-908
        • Brunzell J.D
        • Schrott H.G
        • Motulsky A.G
        • Bierman E.L
        Myocardial infarction in the familial forms of hypertriglyceridemia.
        Metabolism. 1976; 25: 313-320
        • Havel R.J
        Postprandial hyperlipidemia and remnant lipoproteins.
        Curr Opin Lipidol. 1994; 5: 102-109
        • Davignon J
        • Cohn J.S
        Triglyceride.
        Atherosclerosis. 1996; 124: S57-S64
        • Superko H.R
        Beyond LDL cholesterol reduction.
        Circulation. 1996; 94: 2351-2354
        • Grundy S.M
        Small LDL, atherogenic dyslipidemia, and the metabolic syndrome.
        Circulation. 1997; 95: 1-4
        • Brewer Jr, H.B
        • Zech L.A
        • Gregg R.E
        • Schwartz D
        • Schaefer E.J
        NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment.
        Ann Intern Med. 1983; 98: 623-640
        • Hegele R.A
        • Little J.A
        • Vezina C
        • Maguire G.F
        • Tu L
        • Wolever T.S
        • Jenkins D.J
        • Connelly P.W
        Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics.
        Arterioscler Thromb. 1993; 13: 720-728
        • Goldstein J.L
        • Schrott H.G
        • Hazzard W.R
        • Bierman E.L
        • Motulsky A.G
        Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia.
        J Clin Invest. 1973; 52: 1544-1568
        • Stampfer M.J
        • Krauss R.M
        • Ma J
        • Blanche P.J
        • Holl L.G
        • Sacks F.M
        • Hennekens C.H
        A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction.
        JAMA. 1996; 276: 882-888
        • Jeppesen J
        • Hein H.O
        • Suadicani P
        • Gyntelberg F
        Triglyceride concentration and ischemic heart disease.
        Circulation. 1998; 97: 1029-1036
        • Fruchart J.C
        • Brewer Jr, H.B
        • Leitersdorf E
        Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease.
        Am J Cardiol. 1998; 81: 912-917
        • Miller D.B
        • Spence J.D
        Clinical pharmacokinetics of fibric acid derivatives (fibrates).
        Clin Pharmacokinet. 1998; 34: 155-162
        • Kloer H.U
        Structure and biochemical effects of fenofibrate.
        Am J Med. 1987; 83: 3-8
        • Goa K.L
        • Barradell L.B
        • Plosker G.L
        Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
        Drugs. 1996; 52: 725-753
        • Turpin G
        • Bruckert E
        Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
        Atherosclerosis. 1996; 124: S83-S87
        • Betteridge D.J
        Ciprofibrate—a profile.
        Postgrad Med J. 1993; 69: S42-S49
        • Schoonjans K
        • Staels B
        • Auwerx J
        Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression.
        J Lipid Res. 1996; 37: 907-925
        • Wang C.S
        • McConathy W.J
        • Kloer H.U
        • Alaupovic P
        Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
        J Clin Invest. 1985; 75: 384-390
        • Wolfe B.M
        • Kane J.P
        • Havel R.J
        • Brewster H.P
        Mechanism of the hypolipidemic effect of clofibrate on postabsorptive man.
        J Clin Invest. 1973; 52: 2146-2159
        • Vu-Dac N
        • Schoonjans K
        • Kosykh V
        • Dallongeville J
        • Fruchart J.C
        • Staels B
        • Auwerx J
        Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.
        J Clin Invest. 1995; 96: 741-750
        • Zambón D
        • Ros E
        • Rodriguez-Villar C
        • Laguna J.C
        • Havel R.J
        Postprandial hyperlipidemia and remnant lipoproteins.
        Curr Opin Lipidol. 1994; 5: 102-109
        • Tikkanen M.J
        • Laakso M
        • Ilmonen M
        • Helve E
        • Kaarsalo E
        • Kilkki E
        • Saltevo J
        Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.
        Diabetes Care. 1998; 21: 477-481
        • Farnier M
        • Bonnefous F
        • Debbas N
        • Irvine A
        Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
        Arch Intern Med. 1994; 154: 441-449
        • Gholami K
        • Tavakoli N
        • Maleki M
        • Shafiee A
        Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidemia.
        J Clin Pharm Ther. 1998; 23: 213-221
        • Illingworth D.R
        • O’Malley J.P
        The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia.
        Metabolism. 1990; 39: 403-409
        • Athyros V.G
        • Papageorgiou A.A
        • Hatzikonstandinou H.A
        • Didangelos T.P
        • Carina M.V
        • Kranitsas D.F
        • Kontopoulos A.G
        Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
        Am J Cardiol. 1997; 80: 608-613
        • Glueck C.J
        • Oakes N
        • Speirs J
        • Tracy T
        • Lang J
        Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias.
        Am J Cardiol. 1992; 70: 1-9
        • Illingworth D.R
        • Bacon S
        Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia.
        Circulation. 1989; 79: 590-596
        • Pasternak R.C
        • Brown L.E
        • Stone P.H
        • Silverman D.I
        • Gibson C.M
        • Sacks F.M
        Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and “normal” cholesterol levels. A randomized, placebo-controlled trial.
        Ann Intern Med. 1996; 125: 529-540
        • Smit J.W
        • Jansen G.H
        • de Bruin T.W
        • Erkelens D.W
        Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
        Am J Cardiol. 1995; 76: 126A-128A
        • Wicklund O
        • Angelin B
        • Bergman M
        • Berglund L
        • Bonjers G
        • Carlsson A
        • Linden T
        • Miettinen T
        • Odman B
        • Olofsson S.O
        • et al.
        Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia.
        Am J Med. 1993; 94: 13-20
        • Wirebaugh S.R
        • Shapiro M.L
        • McIntyre T.H
        • Whitney E.J
        A retrospective review of the use of lipid-lowering agents in combination, specifically, gemfibrozil and lovastatin.
        Pharmacotherapy. 1992; 12: 445-450
        • Ellen R.L.B
        • McPherson R
        Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
        Am J Cardiol. 1998; 81: 60B-65B
        • Feher M.D
        • Foxton J
        • Banks D
        • Lant A.F
        • Wray R
        Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
        Br Heart J. 1995; 74: 14-17
        • Horsmans Y
        • Desager J.P
        • Harvengt C
        Effects of combined bezafibrate-simvastatin appraised in healthy subjects.
        J Clin Pharmacol. 1992; 32: 422-426
        • Hutchesson A.C
        • Moran A
        • Jones A.F
        Dual bezafibrate-simvastatin therapy for combined hyperlipidemia.
        J Clin Pharm Ther. 1994; 19: 387-389
        • Leitersdorf E
        • Muratti E.N
        • Eliav O
        • Meiner V
        • Eisenberg S
        • Dann E.J
        • Sehayek E
        • Peters T.K
        • Stein Y
        Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia.
        Am J Med. 1994; 96: 401-407
        • Leitersdorf E
        • Muratti E.N
        • Eliav O
        • Peters T.K
        Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
        Am J Cardiol. 1995; 76: 84A-88A
        • Lintott C.J
        • Scott R.S
        • Sharpe D.N
        • Nye E.R
        • Charleson H
        • French J.K
        • White H.D
        • Reuben S
        • Mailing T.J
        • Lewis G.R
        • et al.
        Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation.
        Med J Aust. 1991; 155: 433-436
        • Yeshurun D
        • Abukarshin R
        • Elias N
        • Lanir A
        • Naschitz J.E
        Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
        Clin Ther. 1993; 15: 355-363
        • Pierce L.R
        • Wysowski D.K
        • Gross T.P
        Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.
        JAMA. 1990; 264: 71-75
        • Committee of Principal Investigators
        A co-operative trial in the prevention of ischaemic heart disease using clofibrate.
        Br Heart J. 1978; 40: 1069-1118
        • Committee of Principal Investigators
        WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators.
        Lancet. 1980; 2: 379-385
        • Committee of Principal Investigators
        WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators.
        Lancet. 1984; 15: 600-604
        • Frick M.H
        • Elo O
        • Haapa K
        • Heinonen O.P
        • Heinsalmi P
        • Helo P
        • Huttunen J.K
        • Kaitaniemi P
        • Koskinen P
        • Manninen V
        • Mäenpää H
        • Mälkönen M
        • Mänttäri M
        • Norola S
        • Pasternack A
        • Pikkarainen J
        • Romo M
        • Sjöblom T
        • Nikkilä E.A
        Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
        N Engl J Med. 1987; 317: 1237-1245
        • de Faire U
        • Ericsson C.G
        • Hamsten A
        • Nilsson J
        Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
        Drugs Exp Clin Res. 1995; 21: 105-124
        • Ericsson C.G
        Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
        Eur Heart J. 1998; 19: H37-H41
        • Elkeles R.S
        • Diamond J.R
        • Poulter C
        • Dhanjil S
        • Nicolaides A.N
        • Mahmood S
        • Richmond W
        • Mather H
        • Sharp P
        • Feher M.D
        Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
        Diabetes Care. 1998; 21: 641-648
        • Goldbourt U
        • Behar S
        • Reicher-Reiss H
        • Agmon J
        • Kaplinsky E
        • Graff E
        • Kishon Y
        • Caspi A
        • Weisbort J
        • Mandelzweig L
        Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial).
        Am J Cardiol. 1993; 71: 909-915
        • Goldbourt U
        • Brunner D
        • Behar S
        • Reicher-Reiss H
        Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
        Eur Heart J. 1998; 19: H42-H47
        • Verheugt F.W
        Hotline sessions at the 20th European Congress of Cardiology.
        Eur Heart J. 1999; 20: 7-10
        • Rubins H.B
        • Robins S.J
        • Iwane M.K
        • Boden W.E
        • Elam M.B
        • Fye C.L
        • Gordon D.J
        • Schaefer E.J
        • Schectman G
        • Wittes J.T
        Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.
        Am J Cardiol. 1993; 71: 45-52
        • Papademetriou V
        • Narayan P
        • Rubins H
        • Collins D
        • Robins S
        Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels. HIT Investigators. Department of Veterans Affairs HDL Intervention Trial.
        Am Heart J. 1998; 136: 734-740
        • MAAS Investigators
        Effect of simvastatin on coronary atheroma.
        Lancet. 1994; 344: 633-638
        • Jukema J.W
        • Bruschke A.V
        • van Boven A.J
        • Reiber J.H
        • Bal E.T
        • Zwinderman A.H
        • Jansen H
        • Boerma G.J
        • van Rappard F.M
        • Lie K.I
        • et al.
        Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
        Circulation. 1995; 91: 2528-2540
        • DAIS Project Group
        , Steiner G.
        The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. Diabetologica. 1996; 39: 1655-1661